我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

早期乳腺癌辅助化疗之“去蒽环”之争(PDF)

《医学争鸣》[ISSN:1000-2790/CN:61-1060/R]

期数:
2019年05期
页码:
1-3,7
栏目:
专家论坛
出版日期:
2019-10-31

文章信息/Info

Title:
Debate of “nonanthracycline regimen” for adjuvant chemotherapy of early-stage breast cancer
作者:
延常姣黄美玲李南林
(空军军医大学西京医院甲乳血管外科,陕西 西安 710032)
Author(s):
YAN Changjiao HUANG Meiling LI Nanlin
Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, Xi’an 710032, China
关键词:
蒽环类药物辅助化疗乳腺癌
Keywords:
anthracycline adjuvant chemotherapy breast cancer
分类号:
R73
DOI:
10.13276/j.issn.1674-8913.2019.05.001
文献标识码:
A
摘要:
蒽环类药物是乳腺癌术后辅助化疗的基石,但随着紫杉类药物和靶向药物如曲妥株单抗等新型抗肿 瘤药物的出现,再加上蒽环类药物固有的心脏毒性,使得人们开始思考,蒽环类药物在早期乳腺癌辅助化疗中是 否还有继续存在的价值。多项临床研究也开始了不含蒽环方案的尝试,包括US Oncology 9735、ABC、WSG Plan B、 Success C、BCIRG 006等研究。本文就“去蒽环”的相关临床研究作一梳理,为蒽环类药物在早期乳腺癌辅助化 疗中的治疗提供证据支持。
Abstract:
Anthracycline drugs are the cornerstone of postoperative adjuvant chemotherapy for breast cancer. Because of the inherent heart toxicity of anthracycline and the emergence of new anticancer drugs such as paclitaxel and targeted drugs, it has been considered whether anthracycline drugs should be remained as a regimen of the early breast cancer adjuvant chemotherapy or not. Several clinical studies have tried to discard anthracycline in the adjuvant treatment, including US Oncology 9735, ABC, WSG Plan B, Success C and BCIRG 006 researches, etc. In this paper, we reviewed the related clinical researches of “nonanthracycline regimen” to provide evidence of anthracycline used for the early breast cancer adjuvant chemotherapy.

参考文献/References

[1] 胡夕春, 张 剑, 陈德滇, 等. 中国蒽环类药物治疗乳腺 癌专家共识[J]. 中国肿瘤临床, 2018, 45(3):120-125.
[2] Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15[J]. J Natl Cancer Inst, 2000, 92(24):1991-1998.
[3] Land SR, Kopec JA, Yothers G, et al. Health-related quality of life in axillary node-negative, estrogen receptornegative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23[J]. Breast Cancer Res Treat, 2004, 86(2):153-164.
[4] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472):1687-1717.
[5] Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28[J]. J Clin Oncol, 2005, 23(16):3686-3696.
[6] Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide:7- year follow-up of US Oncology Research Trial 9735[J]. J Clin Oncol, 2009, 27(8):1177-1183.
[7] Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer[J]. J Clin Oncol, 2006, 24(34):5381- 5387.
[8] Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)[J]. J Clin Oncol, 2017, 35(23):2647-2655.
[9] Nitz U, Gluz O, Clemens M, et al. West German Study planB trial:adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer[J]. J Clin Oncol, 2019, 37(10):799-808.
[10] Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial[J]. Breast Cancer Res Treat, 2017, 165(3):573-583.
[11] Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14):1273-1283.
[12] Slamon DJ, Eiermann W, Robert NJ, et al. Abstract S5-04: ten year follow-up of BCIRG006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) withdoxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer[J]. Cancer Res, 2016, 76(4 Supplement):S5-04.
[13] Durbecq V, Paesmans M, Cardoso F, et al. Topoisomerase- II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel[J]. Mol Cancer Ther, 2004, 3(10):1207-1214.
[14] Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracyclinebased therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil[J]. Clin Cancer Res, 2002, 8(5):1107-1116.
[15] Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data[J]. Lancet Oncol, 2011, 12(12):1134-1142.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81472598)
通信作者:李南林。博士,副教授。Tel:13709113279,E-mail:linanlingo@126.com
作者简介:延常姣。硕士,研究实习员。研究方向:乳腺癌诊疗的临床与基础研究。Tel:13572900544,E-mail: ycj617655094@163.com
更新日期/Last Update: 2019-10-31